Tracey McCain
Compliance Officer bei BLUEPRINT MEDICINES CORPORATION
Vermögen: 7 Mio $ am 31.05.2024
Profil
Tracey L.
McCain is an Independent Director at Kiniksa Pharmaceuticals Ltd.
since 2018 and at Blueprint Medicines Corp.
since 2016.
Previously, McCain served as an Independent Director at ImmunoGen, Inc. from 2021 to 2024.
McCain was also the General Counsel at Genzyme Corp.
from 1997 to 2016.
Additionally, McCain worked as an Associate at Palmer & Dodge LLP and as the Senior Vice President & Head-Legal at Genzyme Therapeutics Ltd.
in 2016.
McCain completed an undergraduate degree at the University of Pennsylvania in 1989 and a graduate degree at Columbia Law School in 1992.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 07.03.2024 | 60 498 ( 0,10% ) | 6 Mio $ | 31.05.2024 | |
| 06.06.2024 | 9 373 ( 0,02% ) | 178 181 $ | 31.05.2024 |
Aktive Positionen von Tracey McCain
| Unternehmen | Position | Beginn |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Compliance Officer | 06.09.2016 |
| KINIKSA PHARMACEUTICALS, LTD. | Direktor/Vorstandsmitglied | 01.02.2018 |
Ehemalige bekannte Positionen von Tracey McCain
| Unternehmen | Position | Ende |
|---|---|---|
| IMMUNOGEN, INC. | Direktor/Vorstandsmitglied | 12.02.2024 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | General Counsel | 02.09.2016 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | General Counsel | 01.09.2016 |
| Palmer & Dodge LLP | Corporate Officer/Principal | - |
Ausbildung von Tracey McCain
| University of Pennsylvania | Undergraduate Degree |
| Columbia Law School | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
| Palmer & Dodge LLP | Commercial Services |
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |